Back to Agenda
Session 2 -Submission Predictability in Initial Marketing Authorisation: An Industry Perspective
Session Chair(s)
Aimad Torqui
Head of Division European cooperation and veterinary affairs , MEB, Netherlands
This session examines submission predictability from the industry's perspective, highlighting the challenges and uncertainties faced during the development of a Global Submission. It will illustrate effective case studies where submission dates were adjusted while keeping all key stakeholders and regulators informed in advance. Drawing on available insights & learnings and guidance, the industry will share best practices for planning a submission, strengthening dialogue with regulators and improving predictability of submissions for all stakeholders.
Speaker(s)
Pedro Franco, PHARMD, PHD, MS, MSC
Senior Director for Global Regulatory & Scientific Policy (GRASP), Merck Serono Limited, United Kingdom
Industry representatives’ viewpoints & learnings on submission predictability
Stefan Schwoch, PHD, RPH
VP Global Regulatory Affairs EMEA, Eli Lilly and Company Limited, United Kingdom
Cases studies on submission predictability
Rebecca Lumsden, PHD
Head of Regulatory Science & Policy EU/AMEE, Sanofi, United Kingdom
Have an account?
